Geke A H van den Elsen1, Amir I A Ahmed2, Robbert-Jan Verkes2, Cees Kramers2, Ton Feuth2, Paul B Rosenberg2, Marjolein A van der Marck2, Marcel G M Olde Rikkert2. 1. From the Departments of Geriatric Medicine/Radboudumc Alzheimer Centre (G.A.H.v.d.E., A.I.A.A., M.A.v.d.M., M.G.M.O.R.), Pharmacology and Toxicology (A.I.A.A., C.K.), Psychiatry (R.-J.V.), Internal Medicine (C.K.), and Health Evidence (T.F.), Radboud university medical center, Nijmegen; the Department of Elderly (A.I.A.A.), Vincent van Gogh Institute, Venray; the Department of Clinical Pharmacy (C.K.), Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands; and the Department of Psychiatry and Behavioral Sciences (P.B.R.), John Hopkins University School of Medicine, Baltimore, MD. geke.vandenelsen@radboudumc.nl. 2. From the Departments of Geriatric Medicine/Radboudumc Alzheimer Centre (G.A.H.v.d.E., A.I.A.A., M.A.v.d.M., M.G.M.O.R.), Pharmacology and Toxicology (A.I.A.A., C.K.), Psychiatry (R.-J.V.), Internal Medicine (C.K.), and Health Evidence (T.F.), Radboud university medical center, Nijmegen; the Department of Elderly (A.I.A.A.), Vincent van Gogh Institute, Venray; the Department of Clinical Pharmacy (C.K.), Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands; and the Department of Psychiatry and Behavioral Sciences (P.B.R.), John Hopkins University School of Medicine, Baltimore, MD.
Abstract
OBJECTIVE: To study the efficacy and safety of low-dose oral tetrahydrocannabinol (THC) in the treatment of dementia-related neuropsychiatric symptoms (NPS). METHODS: This is a randomized, double-blind, placebo-controlled study. Patients with dementia and clinically relevant NPS were randomly assigned to receive THC 1.5 mg or matched placebo (1:1) 3 times daily for 3 weeks. Primary outcome was change in Neuropsychiatric Inventory (NPI), assessed at baseline and after 14 and 21 days. Analyses were based on intention-to-treat. RESULTS: Twenty-four patients received THC and 26 received placebo. NPS were reduced during both treatment conditions. The difference in reduction from baseline between THC and placebo was not significant (mean difference NPItotal: 3.2, 95% confidence interval [CI] -3.6 to 10.0), nor were changes in scores for agitation (Cohen-Mansfield Agitation Inventory 4.6, 95% CI -3.0 to 12.2), quality of life (Quality of Life-Alzheimer's Disease -0.5, 95% CI -2.6 to 1.6), or activities of daily living (Barthel Index 0.6, 95% CI -0.8 to 1.9). The number of patients experiencing mild or moderate adverse events was similar (THC, n = 16; placebo, n = 14, p = 0.36). No effects on vital signs, weight, or episodic memory were observed. CONCLUSIONS:Oral THC of 4.5 mg daily showed no benefit in NPS, but was well-tolerated, which adds valuable knowledge to the scarce evidence on THC in dementia. The benign adverse event profile of this dosage allows study of whether higher doses are efficacious and equally well-tolerated. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with dementia-related NPS, low-dose THC does not significantly reduce NPS at 21 days, though it is well-tolerated.
RCT Entities:
OBJECTIVE: To study the efficacy and safety of low-dose oral tetrahydrocannabinol (THC) in the treatment of dementia-related neuropsychiatric symptoms (NPS). METHODS: This is a randomized, double-blind, placebo-controlled study. Patients with dementia and clinically relevant NPS were randomly assigned to receive THC 1.5 mg or matched placebo (1:1) 3 times daily for 3 weeks. Primary outcome was change in Neuropsychiatric Inventory (NPI), assessed at baseline and after 14 and 21 days. Analyses were based on intention-to-treat. RESULTS: Twenty-four patients received THC and 26 received placebo. NPS were reduced during both treatment conditions. The difference in reduction from baseline between THC and placebo was not significant (mean difference NPItotal: 3.2, 95% confidence interval [CI] -3.6 to 10.0), nor were changes in scores for agitation (Cohen-Mansfield Agitation Inventory 4.6, 95% CI -3.0 to 12.2), quality of life (Quality of Life-Alzheimer's Disease -0.5, 95% CI -2.6 to 1.6), or activities of daily living (Barthel Index 0.6, 95% CI -0.8 to 1.9). The number of patients experiencing mild or moderate adverse events was similar (THC, n = 16; placebo, n = 14, p = 0.36). No effects on vital signs, weight, or episodic memory were observed. CONCLUSIONS: Oral THC of 4.5 mg daily showed no benefit in NPS, but was well-tolerated, which adds valuable knowledge to the scarce evidence on THC in dementia. The benign adverse event profile of this dosage allows study of whether higher doses are efficacious and equally well-tolerated. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with dementia-related NPS, low-dose THC does not significantly reduce NPS at 21 days, though it is well-tolerated.
Authors: G A H van den Elsen; A I A Ahmed; M Lammers; C Kramers; R J Verkes; M A van der Marck; M G M Olde Rikkert Journal: Ageing Res Rev Date: 2014-02-05 Impact factor: 10.895
Authors: Linda E Klumpers; Tim L Beumer; Johan G C van Hasselt; Astrid Lipplaa; Lennard B Karger; H Daniël Kleinloog; Jan I Freijer; Marieke L de Kam; Joop M A van Gerven Journal: Br J Clin Pharmacol Date: 2012-07 Impact factor: 4.335
Authors: Barbara S Koppel; John C M Brust; Terry Fife; Jeff Bronstein; Sarah Youssof; Gary Gronseth; David Gloss Journal: Neurology Date: 2014-04-29 Impact factor: 9.910
Authors: Anton P Porsteinsson; Lea T Drye; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos Journal: JAMA Date: 2014-02-19 Impact factor: 56.272
Authors: Matthew R Woodward; David G Harper; Arkadiy Stolyar; Brent P Forester; James M Ellison Journal: Am J Geriatr Psychiatry Date: 2013-04-15 Impact factor: 4.105
Authors: Wilco P Achterberg; Marjoleine J C Pieper; Annelore H van Dalen-Kok; Margot W M de Waal; Bettina S Husebo; Stefan Lautenbacher; Miriam Kunz; Erik J A Scherder; Anne Corbett Journal: Clin Interv Aging Date: 2013-11-01 Impact factor: 4.458
Authors: Donovan T Maust; Erin E Bonar; Mark A Ilgen; Frederic C Blow; Helen C Kales Journal: Am J Geriatr Psychiatry Date: 2016-04-11 Impact factor: 4.105
Authors: Kristoffer H Hellton; Jeffrey Cummings; Audun Osland Vik-Mo; Jan Erik Nordrehaug; Dag Aarsland; Geir Selbaek; Lasse Melvaer Giil Journal: Multivariate Behav Res Date: 2020-04-24 Impact factor: 5.923